Twitter Facebook YouTube Google+ LinkedIn RSS Feed

Next Generation Sequencing Panel for Solid Tumor Cancers [A Test in Focus]

50Gene-Brochure-ButtonThis new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.

 

web-test-info

 

web-useful-for

  • Identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously
  • Identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies
  • Identifying mutations that may help determine prognosis for patients with solid tumors
  • Assisting in establishing a diagnosis (e.g., KIT and PDGFRA alterations for gastrointestinal stromal tumors)
web-specimen
web-clinical-info

When should I order this test?

This test should be ordered to assist in identifying specific mutations within genes known to be associated with response or resistance to specific cancer therapies, and to aid in the diagnosis and prognosis of selected solid tumors.


Key points:

  • The 50-gene solid tumor targeted panel is useful for identifying tumors that may respond to targeted therapies by assessing multiple gene targets simultaneously (eg, assessing multiple RAS/RAF genes to help predict whether advanced colorectal cancers will respond to anti-EGFR therapies).
  • This test can also aid in the diagnosis (eg, KIT and PDGFRA alterations for gastrointestinal stromal tumors) and prognosis (IDH1 alterations in gliomas) of solid tumors.
  • Next generation sequencing is a cost-effective method for assessing multiple genes and uses less DNA than would be required to perform multiple single gene assays.
  • This test can be performed on small formalin-fixed paraffin-embedded tissue specimens.
web-methodname
  • PCR-Based Next Generation Sequencing
    (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)

 

web-performance

  • Day(s) and Time(s) Test Performed: Monday through Friday; varies
  • Analytic Time: 12 days
This entry was posted in Gastrointestinal Cancer, Genetics, Melanoma, Molecular Genetics, Oncology, Skin Cancer, Test in Focus.